INTECH Investment Management’s UroGen Pharma URGN Stock Holding History

INTECH Investment Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$355K	Buy	+9,660	New	+$262K	﹤0.01%	1493
2026 Q1	–	Sell	-22,210	Closed	-$520K	–	2358
2025 Q4	$520K	Buy	22,210 +6,983	+46%	+$151K	﹤0.01%	1500
2025 Q3	$304K	Sell	15,227 -3,675	-19%	-$66K	﹤0.01%	1816
2025 Q2	$259K	Sell	18,902 -7,461	-28%	-$71.6K	﹤0.01%	1958
2025 Q1	$292K	Buy	26,363 +2,374	+10%	+$25.3K	﹤0.01%	1905
2024 Q4	$255K	Buy	23,989 +11,786	+97%	+$141K	﹤0.01%	1911
2024 Q3	$155K	Buy	+12,203	New	+$181K	﹤0.01%	1798

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

INTECH Investment Management's URGN Position: Q2 2026 in Review

INTECH Investment Management opened a new position in UroGen Pharma (URGN) in Q2 2026: 9,660 shares worth $355K. The stake represents ﹤0.01% of the portfolio and ranks #1493 among its holdings. This is a return to the name: INTECH Investment Management previously reported a position in URGN as recently as Q4 2025.

INTECH Investment Management first reported a position in URGN in Q3 2024 and has held it in 7 quarters since. The position peaked at $520K in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

INTECH Investment Management held 9,660 shares of UroGen Pharma worth $355K as of Q2 2026.
UroGen Pharma was a new INTECH Investment Management position in Q2 2026.
UroGen Pharma made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1493 holding.
INTECH Investment Management first reported a position in UroGen Pharma in Q3 2024 and has held it in 7 quarters since.
INTECH Investment Management's UroGen Pharma position peaked at $520K in Q4 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.